HYBENFI
"HYBENFI" is a word mark owned by Eli Lilly and Company, filed at the CIPO on September 5, 2024. It is registered and covers class 5 (Pharmaceuticals).
- Status
- Registered
- Since August 8, 2025
- Filed
- September 5, 2024
- Registered
- August 8, 2025
- Expires
- August 8, 2035
- Application no.
- 2348074
- Registration no.
- TMA1338979
- Office
- CIPO
- Canadian Intellectual Property Office
- Mark type
- Word mark
- 1 class
Who owns HYBENFI
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Eli Lilly and Company
LLY · United States
Representative
Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
What the mark covers
The products and services HYBENFI is filed for, grouped by Nice class.
Pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; pharmaceutical preparations for the prevention and treatment of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain; pharmaceutical preparations for the treatment and the prevention of dementia; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and bacterial skin infections and fungal skin infections; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema, and sexually transmitted diseases; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, Crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, ulcerative colitis; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders, and neuromuscular diseases, namely primary periodic paralysis; pharmaceutical preparations for the treatment of endocrine diseases, namely, glucagonoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of mental health disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for treatment of coronavirus;
What has happened so far
Steps recorded by the CIPO, newest first.
- Registered
- Registration Pending
- Advertised; Vol.72 Issue 3682
- Approval Notice Sent; APPROVED BY PROGRAM EX200M1
- Approved; APPROVED BY PROGRAM EX200M1
- Search Recorded
- Pre-Assessment Letter Sent; Goods or Services Not Acceptable
- Formalized
- Created
- Filed
About HYBENFI
Who owns the trademark "HYBENFI"?
The CIPO trademark "HYBENFI" (application 2348074) is owned by Eli Lilly and Company.
What is the status of "HYBENFI"?
Its status at the CIPO is: registered.
When was "HYBENFI" registered?
It was registered on August 8, 2025 and is due to expire on August 8, 2035.
Get this data via the API
Everything on this page comes from the Signa API. Pull HYBENFI and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019deb4b-6e97-77e2-892c-e8aa0c363274
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019deb4b-6e97-77e2-892c-e8aa0c363274",
"object": "trademark",
"mark_text": "HYBENFI",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "CA",
"application_number": "2348074",
"filing_date": "2024-09-05",
"nice_classes": [
5
],
"owners": [
{
"name": "Eli Lilly and Company",
"entity_id": "ent_019f286c-97ee-774b-84b5-7d5dc09e0b99"
}
]
}